
Cheiron is building an AI-native operating system for drug development, and a drug program generates thousands of artifacts.
Cheiron competes against standard search engines and document-and-spreadsheet workflows by giving biopharma teams a platform to reason over complex hypotheses and operational decisions rather than acting as a standard search engine. Its $8 million seed round backs the view that drug development needs a single software layer rather than a patchwork of documents and spreadsheets.
Across clinical development, regulatory affairs, competitive intelligence, and program leadership workflows, customers use Cheiron to evaluate programs, align stakeholders, and make decisions with greater confidence. The company is building the first AI-native operating system that represents an entire drug program as a single connected system.
The drug-development software category is shifting in Cheiron's favor: when drug development teams face high-stakes operational or clinical decisions, they spend weeks manually reconstructing context rather than advancing therapies, because what has been missing is not the information but a system for representing it. Cheiron uses AI to model the live state of a drug program as a single connected system, a capability that advances in AI and knowledge representation have only recently made possible.
In less than six months since launch, the platform has reached more than 20% of Korea's biopharma knowledge-worker base and secured seven of the country's top 10 biopharma companies as customers.
Cheiron's customer base remains concentrated in Korea, where seven of Korea's top-ten biopharma companies are already customers, while the pilots with leading global pharmaceutical companies that it runs to broaden that base remain active in its U.S. market expansion, so a slowdown there would leave growth reliant on a handful of Korean accounts. Within six months of launch, the platform reached more than 20% of Korea's biopharma knowledge-worker base.
Among Cheiron's users is Boryung, a South Korean pharmaceutical company. The latest funding round will accelerate development of the Life Sciences Knowledge Graph, expand platform capabilities across clinical, regulatory, and strategic workflows, and grow the engineering, product, and life sciences teams.
Cheiron equips biopharma teams with a unified evidence process linking source retrieval to reviewable program outputs. The workflow handles drafting those outputs and verifying claims.
Cheiron produces competitive landscapes, regulatory comparisons, Target Product Profiles, and safety signal write-ups at the program level, prepared for review. It connects protocols, submissions, study results, CMC changes, and regulatory commitments in one place.